NITTO DENKO Avecia Inc.
125 Fortune Boulevard
Avecia, a recognized leader in the development and manufacture of DNA and RNA therapeutics, offers customized solutions and proven expertise that can seamlessly support your oligonucleotide product from small scale modeling to commercial launch. As a part of the Nitto Denko Corporation, Avecia’s commitment to the future is driven by innovative ideas and flexible solutions, designed to provide our customers with the best in service, quality, and technology.
At Avecia’s FDA-inspected cGMP facility, our manufacturing team produces an extensive variety of oligonucleotide API, including antisense, siRNA, aptamers, immunostimulants, miRNA, and molecular decoys. We manufacture to meet the international requirements of ICH Q7, and maintain an outstanding compliance record through customer and FDA audits. We also utilize the guidance of ICH Q8, 9, and 10. Our aim is to leverage our wealth of experience, and knowledge of the regulatory requirements of each market segment, to ensure we exceed our customer’s expectations.
Avecia has 10,000 square feet of controlled space dedicated to the manufacture of oligonucleotides. Within this space are three manufacturing suites, comprised of nine environmentally controlled clean rooms. The operational asset range provides Avecia with the ability to reliably produce single batches ranging from grams to multiple kilograms, with a site capacity of several hundred kilograms per year. There is also ample room for expansion, ready to be developed as needed.
Avecia’s analytical and process development teams have extensive experience, ranging from pre-clinical to clinical compounds and commercial products. We have successfully completed numerous process validations, and have performed technical transfers of compounds at all phases into our facility. Our mission is to build value for our customers as they progress along the drug development journey.
With an integrated supply chain strategy, Avecia is committed to optimizing cost-of-goods against a backdrop of highly complex products being developed in an environment of major timeline and budget challenges. We are equally committed to ensuring the quality, reproducibility and safety of all starting materials.
Whether you are in preclinical stages, or ready for a commercial launch, you can be assured of the best in both technology and service when you turn to the world-leading capabilities of NITTO DENKO Avecia.
NITTO DENKO Avecia Inc.